Elixiron Immunotherapeutics (Cayman) Limited organizes its R&D around immune modulation rather than any single organ or specialty. Chairman Hung-Kai (Kevin) Chen puts it plainly: “We defined ourselves from day one as an immunology company—not ‘oncology,’ not ‘dermatology.’ We develop immune-modulating drugs and then follow the evidence to where they can matter most.” That approach led … Ahead of the Curve: Elixiron’s Immune-First Path to a Vitiligo Lead Read More » To access this post, you must purchase Individual Subscriber Yearly or Enterprise Subscriber.